A carregar...
Optimal duration of adjuvant endocrine therapy: how to apply the newest data
BACKGROUND: The benefit of 5 years of adjuvant endocrine therapy for women with hormone receptor-positive (HR(+)) breast cancer (BC) is beyond discussion. Nevertheless, the risk of recurrence of luminal BC persists for 15 years or more after diagnosis. Consequently, approaches of extended adjuvant t...
Na minha lista:
| Publicado no: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5764154/ https://ncbi.nlm.nih.gov/pubmed/29344105 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834017732966 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|